Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Endocarditis III: Medical Management01:18

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
Endocarditis I: Introduction01:25

Endocarditis I: Introduction

Introduction:Endocarditis is the infection of the endocardium, the inner lining of the heart and its valves. When the heart muscle is involved, the condition is termed myocarditis, while an infection of the outer lining is called pericarditis. Infective endocarditis (IE) primarily affects the endocardium, where pathogens adhere to the valves or lining, forming vegetation that can lead to severe complications. Infective endocarditis occurs when microorganisms, usually bacteria from other body...
Endocarditis IV: Nursing Management01:29

Endocarditis IV: Nursing Management

Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
Pericarditis III: Medical Management01:17

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to White and Siegrist, "Multi-drug-resistant enterococcal infections: duration of combination therapy and OPAT challenges".

Antimicrobial agents and chemotherapy·2026
Same author

Escherichia coli ST131 Drives Carbapenem Use for E. Coli Bloodstream Infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Loss of the ferripyochelin receptor FptA drives reduced cefiderocol susceptibility and impairs fitness in <i>Pseudomonas aeruginosa</i> PA14.

Antimicrobial agents and chemotherapy·2026
Same author

Utilization of Intensive Care Interventions in Critically Ill Patients With Candidemia Versus Bacteremia: A Multicenter Retrospective Cohort Study.

Critical care medicine·2026
Same author

Current Management of Serious Infections due to Vancomycin-resistant Enterococci.

Infectious disease clinics of North America·2026
Same author

Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.

Blood advances·2026
Same journal

Chagas Disease: An Opportunistic Infection in AIDS.

Current infectious disease reports·2026
Same journal

Area-based Deprivation Indices and Healthcare-Associated Infections: A Narrative Review of Evidence.

Current infectious disease reports·2025
Same journal

Next Steps: Studying Diabetic Foot Infections with Next-Generation Molecular Assays.

Current infectious disease reports·2024
Same journal

To Tweet or Not to Tweet-a Review of the Viral Power of Twitter for Infectious Diseases.

Current infectious disease reports·2024
Same journal

Web alert.

Current infectious disease reports·2024
Same journal

Bacterial Vaginosis in Postmenopausal Women.

Current infectious disease reports·2023
See all related articles

Related Experiment Video

Updated: May 21, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Enterococcal endocarditis: can we win the war?

Jose M Munita1, Cesar A Arias, Barbara E Murray

  • 1Laboratory for Antimicrobial Research, University of Texas Medical School at Houston, Houston, TX, USA.

Current Infectious Disease Reports
|June 5, 2012
PubMed
Summary
This summary is machine-generated.

Multidrug-resistant enterococci, especially Enterococcus faecium, present significant challenges for treating infective endocarditis (IE). Limited antibiotic options and high-level resistance complicate patient care globally.

More Related Videos

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
07:50

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues
07:50

An In Vitro Model of a Parallel-Plate Perfusion System to Study Bacterial Adherence to Graft Tissues

Published on: January 7, 2019

Area of Science:

  • Infectious Diseases
  • Clinical Microbiology
  • Cardiology

Background:

  • Enterococcal infections, particularly infective endocarditis (IE), are a significant clinical concern.
  • Increasing prevalence of multidrug-resistant (MDR) enterococci, exhibiting high-level resistance to traditional antibiotics like ampicillin, vancomycin, and aminoglycosides, poses therapeutic dilemmas.
  • Enterococcus faecium strains are increasingly associated with hospital-acquired infections and limited treatment options, unlike more susceptible Enterococcus faecalis.

Purpose of the Study:

  • To highlight the challenges in treating infective endocarditis caused by multidrug-resistant enterococci.
  • To emphasize the limited therapeutic options available for MDR Enterococcus faecium IE.
  • To underscore the ongoing battle against resistant bacterial strains in clinical settings.

Main Methods:

  • Review of current clinical challenges in enterococcal IE treatment.
  • Analysis of antibiotic resistance patterns in Enterococcus faecalis and Enterococcus faecium.
  • Discussion of the impact of MDR strains on therapeutic strategies.

Main Results:

  • Enterococcus faecalis IE often remains treatable with ampicillin and vancomycin.
  • A specific genetic clade of MDR Enterococcus faecium significantly limits treatment choices for IE.
  • Paucity of bactericidal antibiotics against MDR enterococci is a major concern.

Conclusions:

  • Effective treatment strategies for IE caused by MDR Enterococcus faecium are urgently needed.
  • The rise of MDR Enterococcus faecium necessitates the development of new antimicrobial agents.
  • Combating MDR enterococcal infections, especially IE, remains a critical challenge in hospital settings.